The Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-Structure Infections

Clicks: 91
ID: 114102
2004
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Abstract. Daptomycin is the first available agent from a new class of antibiotics, the cyclic lipopeptides, that has activity against a broad range of gram-pos
Reference Key
d.2004clinicalthe Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Arbeit, Robert D.;Maki, Dennis;Tally, Francis P.;Campanaro, Edward;Eisenstein, Barry I.;Daptomycin 98-01 and 99-01 Investigators;
Journal clinical infectious diseases
Year 2004
DOI
DOI not found
URL
http://dx.doi.org/10.1086/420818
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome adult female male aged middle aged Skin Diseases Comparative Study Clinical Trial Phase III Randomized Controlled Trial Multicenter Study anti-bacterial agents / adverse effects penicillins / therapeutic use anti-bacterial agents / administration & dosage anti-bacterial agents / therapeutic use* vancomycin / therapeutic use intravenous soft tissue infections / drug therapy* infectious / drug therapy* infusions pmid:15227611 doi:10.1086/420818 robert d arbeit dennis maki daptomycin 98-01 and 99-01 investigators daptomycin / administration & dosage daptomycin / adverse effects daptomycin / therapeutic use*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.